PDI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Perit Dial Int 29(3): 303-309
2009
© 2009 International Society for Peritoneal Dialysis
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, D. W.

Clinical

THE HONEYPOT STUDY PROTOCOL: A RANDOMIZED CONTROLLED TRIAL OF EXIT-SITE APPLICATION OF MEDIHONEY ANTIBACTERIAL WOUND GEL FOR THE PREVENTION OF CATHETER-ASSOCIATED INFECTIONS IN PERITONEAL DIALYSIS PATIENTS

David W. Johnson1,2, Carolyn Clark1,2, Nicole M. Isbel1,2, Carmel M. Hawley1,2, Elaine Beller1, Alan Cass1,3, Janak de Zoysa1,4, Steven McTaggart1,5, Geoffrey Playford1,6, Brenda Rosser1, Charles Thompson1 and Paul Snelling1,7 the HONEYPOT Study Group

Australasian Kidney Trials Network,1 University of Queensland; Department of Nephrology,2 Princess Alexandra Hospital, Brisbane; The George Institute for International Health,3 Sydney, Australia; Department of Renal Medicine,4 Auckland City Hospital, Auckland, New Zealand; Child & Adolescent Renal Service,5 Royal Children's and Mater Children's Hospitals; Infection Management Services,6 Princess Alexandra Hospital, Brisbane; Department of Nephrology,7 Royal Prince Alfred Hospital, Sydney, Australia

Correspondence to: D. Johnson, Department of Nephrology, Level 2, ARTS Building, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane Qld 4102, Australia. david_johnson{at}health.qld.gov.au

{diamondsuit} Objectives: The primary objective of this study is to determine whether daily exit-site application of standardized antibacterial honey (Medihoney Antibacterial Wound Gel; Comvita, Te Puke, New Zealand) results in a reduced risk of catheter-associated infections in peritoneal dialysis (PD) patients compared with standard topical mupirocin prophylaxis of nasal staphylococcal carriers.

{diamondsuit} Design: Multicenter, prospective, open label, randomized controlled trial.

{diamondsuit} Setting: PD units throughout Australia and New Zealand.

{diamondsuit} Participants: The study will include both incident and prevalent PD patients (adults and children) for whom informed consent can be provided. Patients will be excluded if they have had (1) a history of psychological illness or condition that interferes with their ability to understand or comply with the requirements of the study; (2) recent (within 1 month) exit-site infection, peritonitis, or tunnel infection; (3) known hypersensitivity to, or intolerance of, honey or mupirocin; (4) current or recent (within 4 weeks) treatment with an antibiotic administered by any route; or (5) nasal carriage of mupirocin-resistant Staphylococcus aureus.

{diamondsuit} Methods: 370 subjects will be randomized 1:1 to receive either daily topical exit-site application of Medihoney Antibacterial Wound Gel (all patients) or nasal application of mupirocin if staphylococcal nasal carriage is demonstrated. All patients in the control and intervention groups will perform their usual exit-site care according to local practice. The study will continue until 12 months after the last patient is recruited (anticipated recruitment time is 24 months).

{diamondsuit} Main Outcome Measures: The primary outcome measure will be time to first episode of exit-site infection, tunnel infection, or peritonitis, whichever comes first. Secondary outcome measures will include time to first exit-site infection, time to first tunnel infection, time to first peritonitis, time to infection-associated catheter removal, catheter-associated infection rates, causative organisms, incidence of mupirocin-resistant microbial isolates, and other adverse reactions.

{diamondsuit} Conclusions: This multicenter Australian and New Zealand study has been designed to provide evidence to help nephrologists and their PD patients determine the optimal strategy for preventing PD catheter-associated infections. Demonstration of a significant improvement in PD catheter-associated infections with topical Medihoney will provide clinicians with an important new prophylactic strategy with a low propensity for promoting antimicrobial resistance.

KEY WORDS: Exit-site infection; honey; Medihoney; mupirocin; peritonitis; randomized controlled trial; tunnel infection; bacterial infection; fungal infection.

Received 21 May 2008; accepted 30 September 2008.




This article has been cited by other articles:


Home page
 NDT PlusHome page
S. V. Badve, A. Smith, C. M. Hawley, and D. W. Johnson
Adherence to guideline recommendations for infection prophylaxis in peritoneal dialysis patients
NDT Plus, December 1, 2009; 2(6): 508 - 508.
[Full Text] [PDF]

Home page
 pdiHome page
S. V. Jassal and C. E. Lok
THE HONEYPOT: STICKY OR SWEET?
Perit. Dial. Int., May 1, 2009; 29(3): 267 - 269.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Multimed Inc. logo
Copyright © 2009 by Multimed Inc.